Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial, page-11

@naugthy morty

As I said IMHO

The following is the ann from 10 April 2017:
"Mesoblast Limited (ASX: MSB;Nasdaq: MESO) today announced that the Phase 3 trial of its allogeneic mesenchymal precursor cell(MPC) product candidate MPC-150-IM in patients with moderate to advanced chronic heart failure(CHF) was successful in the pre-specified interim futility analysis of the efficacy endpoint in the trial'sfirst 270 patients. It is expected that the trial will enroll in total approximately 600 patients. Afternotifying the Company of the interim analysis results, the trial’s Independent Data MonitoringCommittee (IDMC) additionally stated that they had no safety concerns relating to MPC-150-IM andformally recommended that the trial should continue as planned."

The reference of "pre-specified interim futility analysis of the efficacy endpoint in the trial'sfirst 270 patients", if not mistaken, is referring to statistically significant positive results which admittedly could be for either primary or secondary endpoints.

As you said, if it showed no improvement, they would have asked WOFTAM. That's the purpose of futility analysis.

Yes, no doubt there might be different interpretations of the meaning of the ann. Hence, please do not rely on the above comment/opinion, and do consult your financial advisor for any investment decision.

Finger crossed we all have a prosperous 2020!